FindTrial
Sign In

A clinical study of mesenchymal stem cell intravenous infusion for severe genodermatosis

A clinical study of mesenchymal stem cell intravenous infusion for severe genodermatosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009596
Enrollment
Unknown
Registered
2016-10-25
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Netherton syndrome

Interventions

treatment group:mesenchymal stem cell intravenous infusion

Sponsors

Xinhua Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1) diagnosed by clinical manifestation,pathology, spink5 gene sequencing,the expression of LEKTI in skin declined or absent; 2) Male and female aged 1 to 17 years; 3) stable life signs; 4) inform consent form.

Exclusion criteria

Exclusion criteria: 1) recieved MSCs therapy in 90 days; 2) recieved immunosupressive therapy in 60 days; 3) allergic to any components of UC-MSCs; 4) allergic to penicillin; 5) history fo branchial asthma; 6) acute infection; 7) chronic infection of HIV, HBV, HCV; 8) poor compliance.

Design outcomes

Primary

MeasureTime frame
expression of LEKTI protein in skin;—

Secondary

MeasureTime frame
expressioin of LEKTI protein in serum;—

Countries

China

Contacts

Public ContactYao Zhirong

Xinhua Hospital, Shanghai Jiaotong University School of Medicine

dermatology.yao@sohu.com+86 13601832440

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026